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Abstract
Background: Despite advances in asthma treatment, severe asthma (SA) still results in high morbidity and use of
health resources. Our hypothesis was that SA patients would achieve adequate control with a systematic protocol,
including oral corticosteroids, budesonide/formoterol maintenance and reliever therapy and a multidisciplinary
approach to improve adherence.
Methods: Non-controlled (NC) SA patients were enrolled to receive 2 weeks of oral corticosteroids and 12 weeks of
formoterol + budesonide. Assessments included asthma control questionnaire (ACQ), asthma control test (ACT),
daily symptom diary, lung function and health-related quality of life (HRQoL) questionnaires.
Results: Of 51 patients, 13 (25.5%) achieved control. NC patients had higher utilization of health resources and
higher exacerbation rates. Both controlled (C) and NC patients had significantly reduced ACQ scores after oral
corticosteroid treatment. After 12 weeks, C patients continued improving. NC patients did not have significant
changes. A similar pattern was found regarding lung function, use of rescue medication, and days free of
symptoms. After 2 weeks of oral corticosteroids, an increase occurred in those who achieved the ACQ cut off;
however, 53.8% of C patients had an ACQ < 1.57 versus 21.1% of NC patients (p = 0.03). Both groups had low
HRQoL at baseline with improvement after intervention.
Conclusions: Despite rigorous, optimized follow-up treatment, 75% of SA patients did not achieve adequate
symptom control and presented with impaired quality of life. Conversely, application of a low-cost, easy to
implement systematic protocol can prevent up to 25% of SA patients from up-titrating to new and complex
therapies, thus reducing costs and morbidity.
Trial registration: Retrospectively registered at ClinicalTrial.gov on 22 February 2010 (NCT01089322).
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Summary at a glance
There is still debate if severe asthma (SA) patients may
acquire symptoms control with available treatment. Our
findings support that the application of a systematic,
low-cost, easy to conduct protocol can prevent up to
25% of uncontrolled SA patients from up titrating their
treatments to new and complex therapies.
Background
The knowledge of the pathogenesis, pathophysiology
and treatment of asthma has made great progress in re-
cent decades. However, several surveys have shown that
a significant part of patients do not achieve adequate
control of the disease despite proper management ac-
cording to guidelines [1, 2]. Factors such as poor access
to medications, lack of medication adherence and envir-
onmental control, patient’s tendency to underestimate
their symptoms, improper use of inhaler devices and
presence of comorbidities have been linked to the inad-
equate symptom control [3].
These factors have a particularly significant impact in
severe asthma (SA), in which this small proportion of pa-
tients is subject to high morbidity and disproportionate
use of health resources [4, 5]. In this subgroup of patients,
the need for a systematic evaluation in a specialized
centre, including confirmation of the diagnosis of asthma,
analysis of comorbidities, patient education, and super-
vised treatment have been suggested. Patients with asthma
who remain uncontrolled despite this approach are con-
sidered to have asthma refractory to treatment [3]. Re-
cently, however, a retrospective analysis by the British
Thoracic Society Network concluded that a systematic ap-
proach is associated with better asthma control, gains in
quality of life (QoL), and reduced health care costs [6].
Several validated tools are available to evaluate asthma
control, such as diaries for symptoms, clinical question-
naires, and inflammatory/functional measurements [7,
8]. Each one has particular advantages, but little data re-
garding their applicability in SA has been published.
Pharmacological trials and systematic protocol assess-
ments use variations in symptom-based questionnaires,
considered as minimally clinically significant values, to
evaluate interventions. The performance of these instru-
ments and the interpretation of results obtained with
them have been questioned [9].
We have previously published the characteristics of a
group of patients who did not reach full clinical control
and maintained persistent airflow limitations, despite
regular monitoring and treatment for at least 4 years -
Brazilian Severe Asthma São Paulo (BRASASP) cohort
[10]. Here, we report the results of a systematic ap-
proach to these patients. Our hypothesis was that most
patients would achieve adequate control with a system-
atic protocol including oral corticosteroids, maintenance
and reliever inhaled corticosteroids (IC) plus long-acting




This was a prospective study including a group of SA
patients already followed in a specialised SA centre
(BRASASP cohort) at least for 1 year. Patients were be-
tween 18 and 65 years old, had confirmed SA treated for
at least 1 year, documented airway reversibility, presence
of at least one asthma exacerbation in the previous year,
were non-smokers or former smokers of ≤ 30 pack-years,
and receiving high-dose IC plus LABA. If the patient
was a smoker, asthma symptoms must have been present
before the onset of smoking, and the patient could not
smoke more than 10 cigarettes/day. The local Institu-
tional Review Board approved this study (CAPPesq 757/
05). All enrolled patients signed an informed consent.
The project was retrospectively registered at Clinical-
Trial.gov on 22 February 2010 (NCT 01089322).
Design overview
The study design is shown in Fig. 1. The patients were
enrolled between January 2007 and December 2009.
They were selected to participate in the study if their
asthma was not controlled according to GINA (Global
Initiative for Asthma) criteria [11]. After a 2-week run-
in period with regular medication to recheck control,
non-controlled SA patients received maintenance ther-
apy with formoterol plus budesonide 12/400mcg twice a
day and reliever medication with formoterol plus bude-
sonide 6/200mcg as needed for 12 weeks. They also re-
ceived an oral corticosteroid (OC) (prednisone) (OC =
40 mg, day-1) in the first 2 weeks after run-in. Patients
were evaluated according to ACQ, ACT, symptom diary,
and spirometry, at baseline (B), after OC (Week [W] 2),
and at the end of the study (W 12). At visit B and W 12,
St George’s Respiratory Questionnaire (SGRQ) and Med-
ical Outcomes Study 36-Item Short Form Health Survey
(SF-36) were administered. In all visits they were seen by
the same investigator, had the use of their inhaler
checked, and compliance with medication assessed by a
count of the remaining doses.
At baseline, all patients self-reported their past medical
history and had their medical records evaluated. Comor-
bidities were evaluated prior to the protocol intervention
as the standard clinical practice of our institution and
aimed to confirm or exclude known diseases related to
non-controlled asthma such as vocal cord dysfunction,
gastroesophageal reflux disease, chronic rhinosinusitis,
and other pulmonary diseases. Whenever present, these
comorbidities were treated according to the same attend-
ing physician.
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Exacerbation was characterized based on the expert
panel of 2009 [12]. Patients who experienced exacerba-
tion of asthma at any time during the study were treated
with prednisone 40 mg/day for seven days, and the
protocol evaluation measurements were postponed for
2 weeks. Antibiotics were prescribed according to phys-
ician judgement for each exacerbation. Total number of
exacerbations was recorded.
Outcome measures
We used ACQ 7 score to measure our primary objective
of asthma control achievement at W12. Patients who
maintained ACQ scores >1.57 were classified as the
non-controlled group (NC) [13].
Secondary clinical outcomes included ACQ 7 score at
W2, the Asthma Control Test (ACT) [14], lung function
results, the St George’s Respiratory Questionnaire
(SGRQ) [15], the Medical Outcomes Study 36-Item
Short Form Health Survey (SF-36) [16], the ratio of days
free of symptoms, and exacerbations.
Statistical analysis
All continuous variables were evaluated for normality
using Kolmogorov-Smirnoff or Shapiro-Wilk tests and
are shown as mean ± standard deviation or median
(IQ25% – 75%). ANOVA repeated measures were used
to compare variables at three moments (B, W2, and
W12) with Bonferroni’s correction. Unpaired t (inde-
pendent groups) was used to analyse the measures be-
tween groups. Wilcoxon Signed-Rank and Mann–
Whitney tests were used for non-parametric variable
analysis. Categorical variables are presented as numbers
and percentages and were analysed with the chi-square
test. Correlations were performed using Pearson or
Spearmen tests whenever appropriate. Multivariable lo-
gistic regression analysis was performed (C versus NC)
with pre-defined relevant clinical variables (age, atopy,
baseline ACQ, baseline FEV1 and asthma duration) to
try do identify predictors of asthma control. The statis-
tical package Sigma Stat version 3.5, Sigma Plot version
10, and PASW Statistics (SPSS) version 18 were used for
statistical analysis. Statistical significance was considered
p < 0.05.
Results
Baseline characteristics of the whole group have been
previously published [10]. From 74 enrolled patients, 54
(72.9%) completed the systematic treatment protocol.
Patients were excluded during follow-up due to lack of
adherence (6 patients), failure to fulfil eligibility criteria
(5 patients), serious adverse events (4 severe exacerba-
tions/1 ischemic heart disease/1 car accident/1 preg-
nancy), and two withdrew informed consent. From those
who completed protocol, 51 (68.9%) patients had all data
available to be analysed.
Of the 51 patients analysed during the 12-week sys-
tematic protocol, 38 (74.5%) did not reach the controlled
criteria of our primary objective (ACQ < 1.57), thus were
classified as the NC group, and 13 (25.5%) achieved con-
trol and were classified as the controlled group (C).
Table 1 compares baseline characteristics of both
groups. NC patients were younger, had shorter duration
of disease and higher prevalence of atopy. NC had more
women, although not statistically significant. Both
groups mainly comprised overweight and obese patients.
No statistical difference was found related to use of oral
Fig. 1 Study design. B: baseline, W: week, ACQ: asthma control questionnaire, ACT: asthma control test, SGRQ: St-George’s Respiratory questionnaire,
SF-36: Medical Outcomes Study 36-Item Short Form Health Survey
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and inhaled corticosteroids as also as previous history of
tobacco exposure.
NC patients had higher previous health care system
utilization. Of NC patients, 71% had more than five hospi-
talizations compared with 38% in C patients (p = 0.05). Re-
garding hospitalization in the last year, no difference existed
between groups (NC 37% versus C 23%). Nearly 40% of pa-
tients of both groups had undergone previous orotracheal
intubation. Regarding comorbidities, there was no differ-
ence between self-reported diseases at baseline.
ACQ analysis showed that both C and NC had a
significant reduction in ACQ score after oral corticoster-
oid treatment (W2). After 12 weeks of follow-up, C
continued to improve, while NC did not (Fig. 2). The
ACQ score was significantly lower in C after treatment
(W12) compared to NC (Table 2). At W2, an increase
occurred in percentage of patients who achieved the cut
off of asthma control in both groups; however, C had
53.8% of patients with ACQ <1.57 versus only 21.1% in
NC group (p = 0.03). Despite not achieving asthma con-
trol, the majority of patients presented a clinically sig-
nificant improvement in their symptoms at the end of
the study, represented by a decrease of at least 0.5 in
ACQ (C = 86.7% versus NC = 66.7% - p = 0.13). We were
unable to identify predictors of asthma control in multi-
variable analysis.
Table 1 Baseline characteristics of non-controlled group (NC), controlled group (C) and not enrolled patients
n (%) NC C Not enrolled (23
patients)38 (74.5) 13 (25.5)
Age (years)† 42 ± 10 51 ± 10* 44 ± 10
Female, n (%) 28 (73) 6 (46) 21 (91)
Education (years) 7.6 ± 3.5 7.7 ± 3.9 8.3 ± 3.1
Asthma age of onset (years) § 9.5 (1 – 31) 1.0 (1 – 18) 9.0 (1 – 22)
Asthma duration (years)† 28 ± 16 41 ± 15* 30 ± 13
BMI (kg/m2)† 30 ± 6 28 ± 6 30 ± 6
Atopy, n (%) 28 (73) 5 (38)* 9 (39)
Non/former smoker, n (%) 23 (60)/15(40) 11 (85)/2(15) 18 (78)/5 (22)
ICS (mcg/day) § 1600 (1200 – 1600) 1600 (1000 – 1600) 1600 (1200 – 1600)
Oral steroids use, n (%) 7 (18) 4 (30) 7 (30)
Prednisone, mg/day§ 20 (15 – 20) 15 (10 – 20) 20 (16 – 20)
BMI body mass index, ICS inhaled corticosteroid, NC non-controlled group, C controlled group
*p < 0.05 between NC and C groups; †Mean ± SD; §median (IQR)
Fig. 2 ACQ behaviour during systematic protocol between controlled and non-controlled groups. B: baseline, W: week. *p < 0.05 (Non-controlled
vs Controlled); a p < 0.05 (W2 vs B); b p < 0.05 (W12 vs B)
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ACT values were significantly higher in C compared to
NC after the course of oral corticosteroids (W2) and at
the end of the protocol (W12) (Table 2). The percentage
of patients with ACT score ≥20 was 30.8% and 69.2% in
the C group at W2 and W12 compared to 13.2% in NC
at both times (p <0.05). A significant correlation was
noted between ACQ and ACT scores in NC patients at
the end of the protocol (r = −0.587, p < 0.001), but not in
C patients.
We observed a significant reduction in rescue medica-
tion use and an expressive increase of days free of symp-
toms in C, which remained until the end of the protocol.
NC patients had no significant change in these variables.
Comparing both groups during the protocol, C patients
needed less rescue medication and had more days free of
symptoms (Table 2).
Evaluation of pulmonary function during follow-up
showed significant improvement in FEV1 and FVC in
both groups after oral corticosteroids. Remarkably, FEV1
and FVC were statistically higher in the C compared
with NC at the end (Table 2). In C, FEV1 was stable be-
tween W2 and W12, although NC patients tended to
lose lung function after oral corticosteroids (Fig. 3).
During the protocol measurements, 29 (56.9%) pa-
tients experienced at least one exacerbation. No differ-
ence existed between C and NC groups (60.5% versus
46.2%g. Nevertheless, there was a higher but not signifi-
cant mean number of exacerbations/patient (1.03 ± 1.1)
in NC compared with C (0.46 ± 0.5).
Both groups had low HRQoL at baseline involving all
SGRG domains. At the end of the intervention, the C
had significantly better HRQoL in all SGRQ domains
(Table 3). The C group tended to have higher percentage
of patients with a ≥4-point change in total control on
the SGRQ (89% vs 61%, p =0.058) compared with NC,
indicating clinical improvement in HRQL. In the SF-36
questionnaire, the two groups reported lower HRQoL at
baseline. As observed in the SGRQ questionnaire, C had
greater improvement in SF-36 measurements than NC
had at the end of protocol.
The ACQ score showed a good correlation with
HRQoL baseline and ending questionnaires, mainly with
SGRQ. Total SGRQ score was positively correlated to
ACQ (r = 0.681; p <0001) and all independent domains
(symptoms: r = 0.724; activity: r = 0.438; impact: r =
0.666). SF-36 correlated with ACQ score in all domains,
except pain.
Discussion
In our SA cohort, despite regular real-life treatment in
our specialized clinic, one-fourth of patients achieved
clinical control in accordance with current asthma con-
trol scores with systematic follow-up. Additionally, we
observed an improvement in QoL scores and lung func-
tion in both groups, although the C group had a more
prominent and sustained behaviour. Our findings sup-
port a controversial discussion about the real possibility
of achieving asthma control in the majority of patients
Table 2 Comparison of ACQ and ACT scores, rescue medication use, days free of symptoms, and lung function parameters
Group (n) NC (38) C (13)
B W2 W12 B W2 W12
ACQ† 3.43 ± 1.14 2.54 ± 1.11a 2.62 ± 0.75 b 2.8 ± 1.06 1.50 ± 0.76* a 0.92 ± 0.22* b
ACT§ 10 (7 – 14) 13 (10 – 14) 13 (12 – 15) 13 (8 – 16) 17 (13 -– 20)* a 21 (19 – 23)* b
Rescue medication (puff/day) § 3.1 (1.1 – 5.3) 2.5 (1.3 – 4.2) a 2.2 (1.0 – 3.4) b 2.7 (1.0 – 6.3) 1.0 (0.2 – 3.0) a 0.4 (0 – 2.3)* b
Days free of symptoms (%)§ 0 (0 – 21) 7 (0 – 33) 0 (0 – 33) 0 (0 – 20) 42 (20 – 84)* a 92 (22 – 100)* b
FVC (%)† 66.8 ± 17.9 76.5 ± 21.3 a 69.5 ± 20.4 68.2 ± 23.3 82.3 ± 15.9 a 83.3 ± 18.5* b
FEV1 (%)
† 49.8 ± 17.3 65.4 ± 22.4a 55.2 ± 19.3b 54.8 ± 19.6 70.7 ± 18.6 a 70.0 ± 21.8* b
FEV1/FVC
† 65 ± 13 65 ± 22 68 ± 13 60 ± 12 70 ± 18 a 70 ± 11 b
FEV1 forced expiratory volume in the first second, FVC forced vital capacity, NC non-controlled group, C controlled group, B baseline, Wweek
*p < 0.05 (NC vs C); a p < 0.05 (W2 vs B); b p < 0.05 (W12 vs B); †Mean ± SD; §median (IQR)
Fig. 3 FEV1 behaviour during systematic protocol between controlled
and non-controlled groups. B: baseline, W: week. *p < 0.05 (Non-con-
trolled vs Controlled); a p < 0.05 (W2 vs B); b p < 0.05 (W12 vs B)
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with severe disease and/or whether we are using the
right tools to evaluate it.
Patients included in this study had uncontrolled
asthma despite regular care in our reference center at a
university hospital. We designed the study with the ex-
pectation that following a systematic protocol and per-
sonalized care (patients were followed at all visits by the
same researcher) would lead to disease control.
All patients were uncontrolled despite regular use of
inhaled corticosteroids associated with LABA, including
the run-in period. During the 12-week study, we applied
a maintenance and reliever strategy with formoterol and
budesonide proven to be effective in patients with
moderate to severe asthma, especially in symptom scores
and number of exacerbations [17]. In the first 2 weeks,
we administered oral corticosteroids to optimize the
response [11, 18, 19].
This strategy was clearly effective in a subset of patients.
The ACQ incorporates seven items (five symptom ques-
tions, one reliever use question, and pre-bronchodilator
FEV1 measurement) and a 1-week recall time. It assesses
the adequacy of asthma control and the change in asthma
control over time. A change in score of > 0.5 is considered
to be clinically important and an ACQ score of 1.57 dis-
criminates between controlled and non-controlled asthma
[13]. Thirteen out of 51 patients achieved a mean ACQ
value less than 1.57 after 2 weeks of oral corticosteroids,
and showed a 1.6 difference in the score from baseline at
12 weeks. This response was accompanied by obvious
improvements in other outcomes, such as ACT (scores
from 20 to 25 were classified as well-controlled asthma;
16–20 as not well controlled; and 5–15 as very poorly
controlled asthma; the minimum clinically significant dif-
ference is 3 points) [14], number of days free of symptoms
and use of rescue medication. The improvement in these
outcomes was reflected in the scores of quality of life
questionnaires. Spirometric parameters followed this im-
provement, but the average FEV1 reached only 70% of
predicted values. These results are in agreement with pre-
vious studies that demonstrated the benefit of applying a
systematic protocol for patients with difficult to control
asthma referred to specialized centers [20, 21]. Our data
show that even in specialized clinics taking care of pa-
tients in real-life conditions a personalized and systematic
strategy is effective, leading to control of patients who
would otherwise be considered non-controlled and suit-
able for a treatment increase.
In the NC group the mean ACQ was 2.54 after the use
of oral corticosteroids and 2.62 at 12 weeks. However
we observed a clinically significant improvement in the
levels of ACQ (0.9 points) and ACT (3 points) after the
use of oral corticosteroids, as well as significant
improvement in FEV1. On the other hand, virtually no
patients were daily free of symptoms during the period.
In the following 10 weeks, despite a higher dose of in-
haled corticosteroids compared to the control group
(shown by the number of rescue doses of formoterol/
budesonide), there was a trend to a clinical and spiro-
metric worsening. Similar response to a course of sys-
temic corticosteroids have been previously reported. ten
Brinke et al. demonstrated a reduction in rescue medica-
tion and an increase in FEV1 2 weeks after intramuscu-
lar triamcinolone in patients with severe asthma who
were using inhaled corticosteroids or chronic oral pred-
nisone [22]. In a recently published study, the re-
searchers of BIOAIR found a higher than 12% increase
in FEV1 after a 2 week course of oral corticosteroids in
15 of 84 patients with severe asthma [18]. The magni-
tude of spirometric response in our group of uncon-
trolled patients after 2 weeks of systemic corticosteroids
demonstrates that a significant functional response to a
course of oral corticosteroids is not necessarily reflected
in adequate control of the disease in the medium and
long term.
We identified a similar profile of patients characterized
by predominantly female gender, long term disease, and
overweight and atopic patients compared to other large
cohorts of SA such as SARP and ENFUMOSA [23, 24].
We found that comorbidities are highly prevalent in pa-
tients with severe asthma not well controlled. Otherwise,
this prevalence was not affected by our intervention,
suggesting that the comorbidities that we evaluated may
not interfere directly in asthma control. These data are
Table 3 Health-related quality of life (HRQoL) scores between
NC and C and asthmatic patients
NC C
B W12 B W12
SGRQ – Total 68 ± 13 62 ± 14 60 ± 13 38 ± 15*
Symptoms 65 ± 18 58 ± 19 58 ± 21 20 ± 17*
Activity 82 ± 17 76 ± 19 73 ± 19 56 ± 19*
Impact 66 ± 12 55 ± 16 57 ± 15 33 ± 16*
SF-36
Physical health
Functional capacity 31 ± 22 38 ± 22 46 ± 20* 58 ± 19*
Physical aspects 21 ± 29 43 ± 40 26 ± 31 68 ± 37
Pain 41 ± 22 47 ± 25 50 ± 23 43 ± 30
General health status 38 ± 18 45 ± 19 49 ± 22 57 ± 19
Mental health
Vitality 42 ± 20 46 ± 20 46 ± 17 60 ± 16*
Social aspects 51 ± 27 60 ± 26 61 ± 26 79 ± 18*
Emotional aspects 36 ± 44 49 ± 41 35 ± 39 83 ± 33*
Mental health 52 ± 24 56 ± 23 54 ± 22 68 ± 16
SGRQ St George’s Respiratory Questionnaire, NC non-controlled group, C con-
trolled group, B baseline, Wweek
Data expressed as mean ± SD; *p < 0.05 (NC vs C)
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in agreement with previous studies, which showed that
in poorly controlled asthmatics there is a high preva-
lence of comorbidity, but no difference in prevalence be-
tween patients who respond or not to treatment [20].
There are some limitations in our study. The relatively
low number of patients in the C group limits the statis-
tical power to some correlations, although the data were
consistent with those previously published [2, 18, 25].
Since this is a single centre study, characterized by a
long-term SA population and public drug access, this
might limit applicability to others health care settings.
We have not covered the full spectrum of comorbid
conditions, nor included an asthma education program
at the visits, which could increase the percentage of con-
trolled patients. In fact, we have demonstrated that
weight reduction leads to asthma control regardless of
asthma treatment [26]. These limitations did not inter-
fere with the main message of our study, namely that a
personalized approach allows asthma control in a signifi-
cant proportion of patients with no change in the medi-
cation for asthma. We were not able to identify which
tool is the best to follow up patients with SA among
spirometry, symptom diary, HRQol, ACQ and ACT.
Nevertheless, we believe that is not possible that only
one tool would be able to discriminate all aspects of
such a heterogeneous disease and that the management
should be based on a combination of them. Finally, it is
a not blinded study. However, since the patients were
already following standard treatment guidelines in a ref-
erence center and were not controlled, we consider it
appropriate not to include a control group.
Our study has important clinical implications. Patients
classified as GINA steps 4 and 5 followed at our asthma
clinic for at least 4 years, with free access to anti-
inflammatory therapies, educational programs and
proper evaluation of factors associated with non-control
composed our population [27–31]. Given the lack of
control add on therapy would be the next natural step to
be implemented in everyday practice. Our systematic
low cost and widely available protocol with optimised
IC + LABA + short course oral corticosteroid was able to
control 25% of patients. The rising cost of medicine and
the pressure to incorporate new technologies are crucial
issues when discussing non-infectious chronic diseases
[32]. Even in developed countries there is a consensus
that the incorporation of high-cost asthma treatments is
justified only to a select group of patients [33, 34]. Our
results highlight the importance of a thorough assess-
ment before considering the indication of these costly
treatments.
Conclusions
Our findings support that in patients with severe uncon-
trolled asthma in daily practice an automatic step up in
treatment may lead to unnecessary increase in expenses
and risks related to new treatments, since the control
can be achieved with a clinical targeted treatment ap-
proach. Nevertheless, despite rigorous and optimized
follow-up treatment, the majority of patients with SA
did not achieve adequate symptom control, and had high
exacerbation rates and impaired QoL. These findings in-
dicate the necessity to redefine the goals and monitoring
tools related to SA. The application of a systematic, low-
cost, easy to conduct protocol can prevent up to 25% of
SA patients from up titrating their treatments to new
and complex therapies, thus reducing costs (possibly)
and morbidity (certainly).
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